Covishield offers protection against COVID-19 that may last a lifetime.

Several studies are investigating the protection duration of Covishield and other COVID-19 vaccines as it is currently unknown.

Several studies are investigating the protection duration of Covishield and other COVID-19 vaccines as it is currently unknown. Some media reports stated that a new study found that Covishield, a COVID-19 vaccine manufactured by the AstraZeneca and Serum Institute of India (SII), offers lifetime protection against COVID-19. The vaccine not only generates virus-busting antibodies but also establishes training camps in the body for search-and-destroy T-cells that can kill even new variants. However, this is currently unverifiable as research is still ongoing about the vaccine's protection duration.

A study published on the bioRxiv website, yet to be peer-reviewed, discovered that immune cells could mature and strengthen for up to a year after infection. The data suggested that immunity is prolonged in convalescents and that convalescents receiving available mRNA vaccines will produce antibodies to protect against the circulation of the coronavirus variants.

The Q&A posted on the SII website confirmed that the vaccine duration of protection has not yet been established.

According to Johns Hopkins Medicine, it is unclear how long the vaccine will be effective in the long run. Data from vaccine trials indicate strong immunity at least months after vaccination, indicating possible long-term immunity.

Even the World Health Organization states that an immune response develops in people recovering from COVID-19 that provides at least a period of reinfection protection. Still, research is ongoing to know the duration of protection by COVID-19 vaccines.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19, including symptoms, prevention, and available treatment, please refer to the World Health Organization or your national healthcare authority.